|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,056.00 DKK | +1.18% |
|
+0.64% | +37.76% |
| 12:00pm | Genmab Presents Promising Data for Epcoritamab in Richter's Transformation | FW |
| 09/12 | Genmab Epcoritamab Achieves Up to 73% Complete Response Across Richter Transformation Trial Arms | MT |
EPS & Dividend: Genmab A/S
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 72.21 | 45.54 | 83.65 | 66.02 | 121.4 | 117 | 100.3 | 131.9 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Reference price 2 | 2,463.00 | 2,630.00 | 2,941.00 | 2,155.00 | 1,492.50 | 2,056.00 | 2,056.00 | 2,056.00 |
| Nbr of stocks (in thousands) | 65,410 | 65,423 | 65,362 | 65,322 | 63,524 | 61,599 | - | - |
| Announcement Date | 23/02/21 | 16/02/22 | 22/02/23 | 14/02/24 | 12/02/25 | - | - | - |
1DKK in Million2DKK
Estimates
Upcoming events: Genmab A/S
More events
| Dividend Yield (N) | Dividend Yield (N+1) | P/E (N) | Price to Book (N) | EV / Sales (N) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | 17.57x | 3.34x | 4.34x | |
| -.--% | -.--% | 50.93x | 8.28x | 12.4x | |
| -.--% | -.--% | -31.88x | 63.71x | 80.89x | |
| 1.75% | 1.66% | 16.2x | 3.82x | 5.68x | |
| -.--% | -.--% | -25.86x | 1.12x | 3.49x | |
| -.--% | -.--% | 27.79x | 2.57x | 5.44x | |
| -.--% | -.--% | -514.7x | 14.1x | 29.79x | |
| -.--% | -.--% | -14.46x | - | 181.97x | |
| -.--% | -.--% | -190.92x | 23.07x | 47.06x | |
| -.--% | -.--% | -57.95x | 21.39x | 13.02x | |
| Average | 0.17% | 0.17% | -72.33x | 15.71x | 38.41x | |
| Weighted average by Cap. | 0.27% | 0.25% | -34.66x | 17.70x | 33.37x |
Year-on-year evolution of the Yield
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Estimates Revisions
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Annual Profit -
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition